Pfizer Investor Presentation — July 2024

Document content

Breakthroughs that change patients' lives ®

July 30, 2024Second Quarter 2024

Earnings TeleconferenceIntroduction

Chief Investor Relations Officer,

Senior Vice President3

Second Quarter 2024 EarningsForward-Looking Statements and Non-GAAP Financial Information

l Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ

materially from those expressed or implied by such statements. We include forward-looking statements about, among other topics, our anticipated operating and financial

performance, including financial guidance and projections; changes to Pfizer's commercial organization; reorganizations; business plans, strategy, goals and prospects; our

Environmental, Social and Governance (ESG) priorities, strategy and goals; expectations for our product pipeline, in-line products and product candidates, including anticipated

regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and

reimbursement, potential market dynamics, including demand, market size and utilization rates and growth, performance, timing of exclusivity and potential benefits; strategic reviews;

capital allocation objectives; an enterprise-wide cost realignment program (including anticipated costs, savings and potential benefits); a manufacturing optimization program to reduce

our cost of goods sold (including anticipated costs, savings and potential benefits); dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and

other business development activities, including our December 2023 acquisition of Seagen, and our ability to successfully capitalize on growth opportunities and prospects;